# β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

> **NCT00888797** · PHASE3 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 400 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Propranolol and Etodolac

## Key facts

- **NCT ID:** NCT00888797
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2011-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888797, "β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00888797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*